Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesper Bonde

Showing results (21-30 of 84) with videos related to

Pageof 9
Sort By:
Gynecologic Oncology|December 3, 2014
Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytologyMatejka Rebolj, Elsebeth Lynge, Ditte Ejegod, et al.
BMC Cancer|July 22, 2016
Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample studySarah Preisler, Matejka Rebolj, Ditte Møller Ejegod, et al.
The Journal of Molecular Diagnostics : JMD|July 6, 2013
Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assayMatejka Rebolj, Sarah Preisler, Ditte M Ejegod, et al.
BMC Infectious Diseases|July 28, 2014
HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray systemJesper Bonde, Matejka Rebolj, Ditte Møller Ejegod, et al.
The Journal of Molecular Diagnostics : JMD|February 5, 2022
Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 FrameworkHelle Pedersen, Ditte M Ejegod, Wim Quint, et al.
Plos One|January 28, 2014
Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screeningMatejka Rebolj, Sarah Preisler, Ditte Møller Ejegod, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 4, 2021
The challenges of defining sample adequacy in an era of HPV based cervical screeningKate Cuschieri, Allan Wilson, Timothy Palmer, et al.
Ugeskrift for Laeger|March 4, 2022
[Phased implementation of HPV-based cervical cancer screening in Denmark]Jesper Bonde, Jeppe Bennekou Schroll, Bettina Kjær Kristensen, et al.
Preventive Medicine|February 7, 2024
Cervical cancer screening activity in the Capital Region of Denmark before, during and after the COVID-19 pandemicBirgitte Tønnes Pedersen, Helle Pedersen, Reza Serizawa, et al.
Plos One|March 28, 2013
Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assaySarah Preisler, Matejka Rebolj, Anette Untermann, et al.
Pageof 9

Showing results (21-30 of 84) with videos related to

Sort By:
Pageof 9
Gynecologic Oncology|December 3, 2014
Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytologyMatejka Rebolj, Elsebeth Lynge, Ditte Ejegod, et al.
BMC Cancer|July 22, 2016
Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample studySarah Preisler, Matejka Rebolj, Ditte Møller Ejegod, et al.
The Journal of Molecular Diagnostics : JMD|July 6, 2013
Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assayMatejka Rebolj, Sarah Preisler, Ditte M Ejegod, et al.
BMC Infectious Diseases|July 28, 2014
HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray systemJesper Bonde, Matejka Rebolj, Ditte Møller Ejegod, et al.
The Journal of Molecular Diagnostics : JMD|February 5, 2022
Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 FrameworkHelle Pedersen, Ditte M Ejegod, Wim Quint, et al.
Plos One|January 28, 2014
Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screeningMatejka Rebolj, Sarah Preisler, Ditte Møller Ejegod, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 4, 2021
The challenges of defining sample adequacy in an era of HPV based cervical screeningKate Cuschieri, Allan Wilson, Timothy Palmer, et al.
Ugeskrift for Laeger|March 4, 2022
[Phased implementation of HPV-based cervical cancer screening in Denmark]Jesper Bonde, Jeppe Bennekou Schroll, Bettina Kjær Kristensen, et al.
Preventive Medicine|February 7, 2024
Cervical cancer screening activity in the Capital Region of Denmark before, during and after the COVID-19 pandemicBirgitte Tønnes Pedersen, Helle Pedersen, Reza Serizawa, et al.
Plos One|March 28, 2013
Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assaySarah Preisler, Matejka Rebolj, Anette Untermann, et al.
Pageof 9